JNK pathway-associated phosphatase associates with rheumatoid arthritis risk, disease activity, and its longitudinal elevation relates to etanercept treatment response

JNK pathway-associated phosphatase associates with rheumatoid arthritis risk, disease activity, and its longitudinal elevation relates to etanercept treatment response

Background: This study aimed to investigate the relationship of serum JNK pathway-associated phosphatase (JKAP) expression with rheumatoid arthritis (RA) risk and clinical features, also to explore the longitudinal change of JKAP during etanercept treatment and its relationship with etanercept treat...

Full description

Bibliographic Details
Main Authors: Chen, X. (Author), Dai, M. (Author), Liu, C. (Author), Sun, L. (Author), Tu, J. (Author), Xia, X. (Author), Zhou, Y. (Author)
Format: Article
Language:English
Published: John Wiley and Sons Inc 2021
Subjects:
adult
Arthritis, Rheumatoid
Article
C reactive protein
cohort analysis
controlled study
DAS28
disease activity
disease risk
disease severity
drug efficacy
dual specificity phosphatase
Dual-Specificity Phosphatases
DUSP22 protein, human
enzyme linked immunosorbent assay
enzymology
erythrocyte sedimentation rate
etanercept
Etanercept
etanercept treatment
female
Female
human
Humans
JNK pathway-associated phosphatase
leflunomide
longitudinal study
major clinical study
male
Male
metabolism
methotrexate
middle aged
Middle Aged
mitogen activated protein kinase phosphatase
Mitogen-Activated Protein Kinase Phosphatases
pathogenesis
pathology
patient participation
phosphatase
predictive value
Predictive Value of Tests
protein blood level
protein expression
receiver operating characteristic
rheumatoid arthritis
risk factor
Risk Factors
ROC Curve
signal transduction
stress activated protein kinase
swollen joint count
tender joint count
treatment duration
treatment outcome
Treatment Outcome
treatment response
Online Access:View Fulltext in Publisher

Internet

View Fulltext in Publisher

Similar Items